Yüklüyor......
Erlotinib Plus Bevacizumab Phase ll Study in Patients with Advanced Non-small-Cell Lung Cancer (JO25567): Updated Safety Results
INTRODUCTION: The phase II JO25567 study compared the efficacy and safety of erlotinib plus bevacizumab vs. erlotinib alone as first-line therapy for advanced epidermal growth factor receptor (EGFR) mutation-positive non-small-cell lung cancer (NSCLC). OBJECTIVE: Our objective is to provide updated...
Kaydedildi:
| Yayımlandı: | Drug Saf |
|---|---|
| Asıl Yazarlar: | , , , , , , , , , , , , |
| Materyal Türü: | Artigo |
| Dil: | Inglês |
| Baskı/Yayın Bilgisi: |
Springer International Publishing
2017
|
| Konular: | |
| Online Erişim: | https://ncbi.nlm.nih.gov/pmc/articles/PMC5808045/ https://ncbi.nlm.nih.gov/pubmed/29043496 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1007/s40264-017-0596-0 |
| Etiketler: |
Etiketle
Etiket eklenmemiş, İlk siz ekleyin!
|